News
StockStory.org on MSN2d
Gilead Sciences’s Q2 Earnings Call: Our Top 5 Analyst Questions
Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
Despite decades of medical progress, HIV continues to devastate Black communities. The statistics are sobering. The ...
Also Read: Gilead Sciences/Merck’s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks HIV product sales increased 9% to $5.1 billion, with Biktarvy sales ...
The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.
(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over ...
Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...
Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...
At Gilead Sciences, a company focused on advances and innovations in medications for HIV, hepatitis and cancer, Dr. Nwafor emphasizes that breakthrough treatments are only effective when paired ...
Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump ...
22h
Zacks Investment Research on MSNIs Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results